382 related articles for article (PubMed ID: 12444809)
21. Clinical trials in Alzheimer's disease. Calculating Alzheimer's Disease Assessment Scale-cognitive subsection with the data from the consortium to establish a registry for Alzheimer's disease.
Gillen TE; Gregg KM; Yuan H; Kurth MC; Krishnan KR
Psychopharmacol Bull; 2001; 35(2):83-96. PubMed ID: 12397889
[TBL] [Abstract][Full Text] [Related]
22. Predictive value of 6-month decline in ADAS-cog for survival without severe Alzheimer's disease.
Helmer C; Andrieu S; Pérès K; Orgogozo JM; Vellas B; Dartigues JF;
Dement Geriatr Cogn Disord; 2007; 23(3):168-74. PubMed ID: 17215578
[TBL] [Abstract][Full Text] [Related]
23. Alzheimer's Disease Assessment Scale: reliability and validity in a multicenter clinical trial.
Weyer G; Erzigkeit H; Kanowski S; Ihl R; Hadler D
Int Psychogeriatr; 1997 Jun; 9(2):123-38. PubMed ID: 9309486
[TBL] [Abstract][Full Text] [Related]
24. Vagus nerve stimulation (VNS) for treatment-resistant depression: efficacy, side effects, and predictors of outcome.
Sackeim HA; Rush AJ; George MS; Marangell LB; Husain MM; Nahas Z; Johnson CR; Seidman S; Giller C; Haines S; Simpson RK; Goodman RR
Neuropsychopharmacology; 2001 Nov; 25(5):713-28. PubMed ID: 11682255
[TBL] [Abstract][Full Text] [Related]
25. Lithium trial in Alzheimer's disease: a randomized, single-blind, placebo-controlled, multicenter 10-week study.
Hampel H; Ewers M; Bürger K; Annas P; Mörtberg A; Bogstedt A; Frölich L; Schröder J; Schönknecht P; Riepe MW; Kraft I; Gasser T; Leyhe T; Möller HJ; Kurz A; Basun H
J Clin Psychiatry; 2009 Jun; 70(6):922-31. PubMed ID: 19573486
[TBL] [Abstract][Full Text] [Related]
26. Linking the Mini-Mental State Examination, the Alzheimer's Disease Assessment Scale-Cognitive Subscale and the Severe Impairment Battery: evidence from individual participant data from five randomised clinical trials of donepezil.
Levine SZ; Yoshida K; Goldberg Y; Samara M; Cipriani A; Efthimiou O; Iwatsubo T; Leucht S; Furukawa TA
Evid Based Ment Health; 2021 May; 24(2):56-61. PubMed ID: 33023920
[TBL] [Abstract][Full Text] [Related]
27. Computerized cognition assessment during acetylcholinesterase inhibitor treatment in Alzheimer's disease.
Wesnes K; Edgar C; Andreasen N; Annas P; Basun H; Lannfelt L; Zetterberg H; Blennow K; Minthon L
Acta Neurol Scand; 2010 Oct; 122(4):270-7. PubMed ID: 20047570
[TBL] [Abstract][Full Text] [Related]
28. Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer's disease.
Morris JC; Cyrus PA; Orazem J; Mas J; Bieber F; Ruzicka BB; Gulanski B
Neurology; 1998 May; 50(5):1222-30. PubMed ID: 9595967
[TBL] [Abstract][Full Text] [Related]
29. A study of the Alzheimer's Disease Assessment Scale-Cognitive (ADAS-Cog) in an Icelandic elderly population.
Hannesdóttir K; Snaedal J
Nord J Psychiatry; 2002; 56(3):201-6. PubMed ID: 12079572
[TBL] [Abstract][Full Text] [Related]
30. Effects of a newly developed cognitive intervention in amnestic mild cognitive impairment and mild Alzheimer's disease: a pilot study.
Buschert VC; Friese U; Teipel SJ; Schneider P; Merensky W; Rujescu D; Möller HJ; Hampel H; Buerger K
J Alzheimers Dis; 2011; 25(4):679-94. PubMed ID: 21483095
[TBL] [Abstract][Full Text] [Related]
31. [Validation of the Hungarian version of Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) in patients with mild cognitive impairment].
Papp E; Pákáski M; Drótos G; Kálmán J
Psychiatr Hung; 2012; 27(6):426-34. PubMed ID: 23429337
[TBL] [Abstract][Full Text] [Related]
32. Real-World, Multinational, Retrospective Observational Survey of the ADAS-Cog and Associations with Healthcare Resource Utilization in Patients with Alzheimer's Disease.
Ritchie CW; Khandker RK; Pike J; Black CM; Jones E; Ambegaonkar BM
J Alzheimers Dis; 2018; 64(3):899-910. PubMed ID: 29966202
[TBL] [Abstract][Full Text] [Related]
33. [Is it pseudo-dementia? The validation of the Adas-Cog questionnaire in Hungary].
Drótos G; Pákáski M; Papp E; Kálmán J
Psychiatr Hung; 2012; 27(2):82-91. PubMed ID: 22700619
[TBL] [Abstract][Full Text] [Related]
34. A randomized controlled trial of high-dose vitamin D2 followed by intranasal insulin in Alzheimer's disease.
Stein MS; Scherer SC; Ladd KS; Harrison LC
J Alzheimers Dis; 2011; 26(3):477-84. PubMed ID: 21694461
[TBL] [Abstract][Full Text] [Related]
35. Domain-specific improvement of cognition on memantine in patients with Alzheimer's disease treated with rivastigmine.
Riepe MW; Adler G; Ibach B; Weinkauf B; Tracik F; Gunay I
Dement Geriatr Cogn Disord; 2007; 23(5):301-6. PubMed ID: 17356273
[TBL] [Abstract][Full Text] [Related]
36. Effects of AZD3480 on cognition in patients with mild-to-moderate Alzheimer's disease: a phase IIb dose-finding study.
Frölich L; Ashwood T; Nilsson J; Eckerwall G;
J Alzheimers Dis; 2011; 24(2):363-74. PubMed ID: 21258153
[TBL] [Abstract][Full Text] [Related]
37. The stability of AQT processing speed, ADAS-Cog and MMSE during acetylcholinesterase inhibitor treatment in Alzheimer's disease.
Wiig EH; Annas P; Basun H; Andreasen N; Lannfelt L; Zetterberg H; Blennow K; Minthon L
Acta Neurol Scand; 2010 Mar; 121(3):186-93. PubMed ID: 19785641
[TBL] [Abstract][Full Text] [Related]
38. Response patterns of EGb 761 in Alzheimer's disease: influence of neuropsychological profiles.
Le Bars PL
Pharmacopsychiatry; 2003 Jun; 36 Suppl 1():S50-5. PubMed ID: 13130389
[TBL] [Abstract][Full Text] [Related]
39. A randomised pilot study to assess the efficacy of an interactive, multimedia tool of cognitive stimulation in Alzheimer's disease.
Tárraga L; Boada M; Modinos G; Espinosa A; Diego S; Morera A; Guitart M; Balcells J; López OL; Becker JT
J Neurol Neurosurg Psychiatry; 2006 Oct; 77(10):1116-21. PubMed ID: 16820420
[TBL] [Abstract][Full Text] [Related]
40. Examining the reliability of ADAS-Cog change scores.
Grochowalski JH; Liu Y; Siedlecki KL
Neuropsychol Dev Cogn B Aging Neuropsychol Cogn; 2016 Sep; 23(5):513-29. PubMed ID: 26708116
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
